The Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED

Size: px
Start display at page:

Download "The Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED"

Transcription

1 JCM Accepts, published online ahead of print on 7 May 2008 J. Clin. Microbiol. doi: /jcm Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. 1 The Impact of meca Gene Testing and Infectious Diseases Pharmacists Intervention on the Time to Optimal Antimicrobial Therapy for AUTHORS: Staphylococcus aureus Bacteremia at a University Hospital Peggy L. Carver, Pharm.D., FCCP* Clinical Pharmacist in Infectious Diseases and Associate Professor University of Michigan Health System and College of Pharmacy Shu-Wen Lin, M.S., Pharm.D. (No middle initial) At the time of the study: Specialty Resident in Infectious Diseases and Clinical Instructor University of Michigan Health System and College of Pharmacy Departments of Pharmacy Services and Clinical Sciences University of Michigan Health System Current position: Pharmacist and Lecturer National Taiwan University Hospital and Graduate Institute of Clinical Pharmacy Daryl D. DePestel, Pharm.D. Clinical Pharmacist in Infectious Diseases and Clinical Assistant Professor University of Michigan Health System and College of Pharmacy

2 2 Duane W. Newton, Ph.D., D(ABMM) Director, Clinical Microbiology Laboratories and Assistant Professor Department of Pathology University of Michigan Health System and Medical School Corresponding Author and Author to whom Reprint Requests should be directed: Peggy L. Carver, Pharm.D., FCCP Clinical Pharmacist in Infectious Diseases and Associate Professor University of Michigan Health System and College of Pharmacy Address: University of Michigan College of Pharmacy, Department of Clinical Sciences 428 Church Street Ann Arbor, MI Phone: (734) Fax: (734) No funding or conflict of interest information to disclose with respect to this publication. Presented as a poster at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, December 16-19, 2005.

3 3 Running title: meca Testing and Time to Optimal Antimicrobial Therapy Key words: meca gene, gram-positive, methicillin-resistant, Staphylococcus aureus, methicillin-susceptible, susceptibility testing, intervention, antimicrobial pharmacist, optimal antimicrobial therapy

4 1 1 Abstract In patients with Staphylococcus aureus bacteremia, Infectious Diseases pharmacist intervention based on the results of meca tests resulted in a a 25.4 hour reduction in the time to optimal antimicrobial therapy, from 64.7 ± 36.8 to 39.3 ± 15.5 hours (p = 0.002), which may result in decreased mortality.

5 Although the most accurate testing method for the detection of MRSA, the meca gene test is not widely used at hospitals, and many clinicians lack knowledge regarding the appropriate and timely application of meca gene test results for the selection of optimal antimicrobial therapy (OAT) against S. aureus infections. Our microbiology laboratory routinely performs meca gene polymerase chain reaction (PCR) testing on all staphylococci once daily, 6 days/week; results are generally available within 36 hours after growth of the organism in culture. However, an additional 2-4 days elapse before the availability of final in vitro susceptibility testing results (i.e., oxacillin susceptibility using cefoxitin as the indicator drug). We hypothesized that the use of an ID clinical pharmacist to alert physicians and to provide clinical recommendations regarding specific antimicrobial therapy at the time of meca gene test availability would decrease the time to receipt of optimal OAT. We compared the time to prescribing of OAT following positive blood culture results with or without ID pharmacist intervention, to evaluate the impact of an ID pharmacistbased meca result notification program on the percentage of patients receiving optimal anti-staphylococcal therapy as compared to a historical control group (standard of care). The study consisted of 2 consecutive, prospective study phases. Phase I was a pilot phase with concurrent quality-assurance surveillance of antimicrobial agents in patients with SAB, without ID pharmacist intervention. During Phase II, the ID pharmacist was alerted daily by the microbiology laboratory when the results of the meca gene tests were available. At that time, patient records were assessed to determine target patients, defined as those who were not currently receiving OAT. The

6 target patients physician was contacted by phone to explain the interpretation of the meca gene test result, and to offer recommendations for therapy. All target patients who met the selection criteria were enrolled into the study. During Phase II (but not Phase I), all patients received ID pharmacist intervention. Institutional review board (IRB) approval was obtained for this study. For purposes of this investigation, appropriate antimicrobial therapy was defined as microbiologically documented SAB that was effectively treated with antimicrobials at the time of its identification, and optimal antimicrobial therapy as any regimen containing vancomycin for MRSA bacteremia, and any regimen containing nafcillin, - lactam/ -lactamase inhibitor combinations, first-, or fourth-generation cephalosporins, or vancomycin for MSSA. Vancomycin was not considered optimal therapy for MSSA SAB except in patients with true allergic reactions or severe adverse reactions (eg, neutropenia) to -lactam antibiotics. Vancomycin alternatives (e.g. linezolid, quinupristin/dalfopristin, or daptomycin) were considered optimal if patients had a true vancomycin allergy, were vancomycin intolerant, or had a documented treatment failure on vancomycin. Additionally, only nafcillin was considered optimal therapy if the patient had concurrent meningitis or endocarditis due to MSSA. The primary objective of this study was to evaluate the impact of infectious diseases (ID) pharmacists interventions on the adjustment of antimicrobial therapy based on meca gene tests, and the primary endpoint was the difference in time (hours) to optimal anti-staphylococcal antimicrobial therapy for SAB between Phases I and II. Secondary endpoints included the time to OAT and the rate of application of

7 meca gene test results to antimicrobial regimen adjustment in the period prior to or with the ID pharmacist s interventions Statistical analysis was performed utilizing Statview (SAS Institute Inc., Cary, NC). The t test (or Mann-Whitney U test for nonparametric data) was used to compare the differences in time to optimal antibiotic therapy prior to and after implementation of pharmacy intervention. The Pearson chi-square test was applied on categorical variables of target groups between the two study phases with 2 2 tables. A p-value less than 0.05 was considered significant. The time to optimal antimicrobial therapy following the drawing of a SAB was 64.7 ± 36.8 hours in Phase I and 39.3 ± 15.5 hours in Phase II (p=0.002), a 25.4 h reduction in the time to optimal antimicrobial therapy. (Table 1, Figure 1). The sample size of this study is insufficient to evaluate or compare infection-related outcomes or mortality; however, and a trend towards a decrease in the duration of SAB was observed. An additional benefit during the intervention phase was the discontinuation or de-escalation of inappropriate therapy, which can more effectively target the causative pathogen, resulting in decreased inappropriate antimicrobial exposure. Timely use of appropriate empiric antimicrobial therapy and of specific antimicrobial therapy-based susceptibility results are important determinants of clinical outcomes in S. aureus bacteremia (SAB). In a retrospective cohort study of 64 patients with MSSA and 103 patients with MRSA, delayed treatment of hospitalacquired SAB was associated with a higher infection-related mortality and a longer length of hospital stay (p = 0.05). The breakpoint between early and delayed treatment was hours from the draw time of the first positive SAB blood culture

8 (1). The strongest clinical evidence to date supporting the concept that vancomycin is inferior to nafcillin in treating MSSA SAB is from Chang et al (2), who found that nafcillin was superior to vancomycin in preventing persistent bacteremia or relapse in 77 patients with MSSA SAB. More recently, Stryjewski and colleagues (3) noted that 78 hemodialysis-dependent patients treated with cefazolin (vs vancomycin) for MSSA 79 bacteremia experienced a lower risk of treatment failure. 80 The meca PCR test provides rapid identification of MRSA compared to 81 traditional susceptibility testing methods and can be used to tailor OAT in a timely 82 fashion. Novel methods to detect and differentiate between MSSA and MRSA directly 83 from blood culture bottles have recently become available (4). However, the clinician s 84 utilization of this information is vital for tailoring the timely use of optimal antimicrobial 85 treatment. Despite the availability of the meca test, prescribers failed to utilize the 86 results without pharmacists intervention. Pharmacists intervention based on the 87 meca gene test resulted in a 25.4 h reduction in the time to OAT, and a trend towards 88 a decrease in the duration of SAB. These results may result in decrease morbidity and 89 mortality in patients with SAB; further clinical study is needed in order to assess this possibility. 90

9 6 91 References Lodise T.P., P.S. McKinnon, L. Swiderski, and M.J. Rybak Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36: Chang F.Y., B.B. MacDonald, J.E. Peacock Jr, D.M. Musher, P. Triplett, J.M. Mylotte, A. O'Donnell, M.M. Wagener, and V.L. Yu A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore). 82: Stryjewski M.E., L.A. Szczech, D.K. Benjamin Jr, J.K. Inrig, Z.A. Kanafani, J.J. Engemann, V.H. Chu, M.J. Joyce, L.B. Reller, G.R. Corey, and Fowler V.G. Jr Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44: Huletsky A., P. Lebel, F.J. Picard, M. Bernier, M. Gagnon, N. Boucher, and M.G. Bergeron Identification of methicillin-resistant Staphylococcus aureus carriage in less than 1 hour during a hospital surveillance program. Clin. Infect. Dis. 40:

10 Table 1 Demographic characteristics, comorbidities, antimicrobial therapy, and species of staphylococci identified for 46 patients with Staphylococcus aureus bacteremia enrolled in the study. a Phase I Phase II P Demographic Characteristic (no.=30) (no.=16) Age in years (mean ± SD) 49.3 ± ± Range in years Male sex 20 (66.6) 8 (50.0) 0.27 MSSA (meca gene absent) 24 (80.0) 15 (93.8) 0.22 Duration of Staphylococcus aureus 3.2 ± ± bacteremia (days) ID consult service b 13 (43.3) 10 (62.5) 0.24 Empiric antimicrobial therapy Vancomycin 23 (76.7) 15 (94.4) lactam/ -lactamase inhibitor 3 (10.0) 0 (0.0) /4 generation cephalosporin c 0 (0.0) 0 (0.0) Other antimicrobial agents 4 (13.3) 1 (6.3) Specific antimicrobial therapy 127 Vancomycin 6 (20.0) 1 (6.3) Nafcillin 12 (40.0) 7 (43.8) 0.74

11 lactam/ -lactamase inhibitor 4 (13.3) 3 (18.8) /4 generation cephalosporin 6 (20.0) 5 (31.3) 0.39 Other antimicrobial agents 2 (6.7) 0 (0.0) 0.29 a Data are presented as the number (percentage) of patients b Patient was seen by the Infectious Diseases consult service c 1/4 generation cephalosporin = first or fourth generation anti-staphylococcal cephalosporin MSSA = methicillin susceptible Staphylococcus

12 Figure 1. Time frame for the collection of SAB blood cultures, the reporting of meca gene test and susceptibility tests for S. aureus, and time to optimal antimicrobial therapy during Phases I and II. Data are reported in hours.

13 Time to optimal antimicrobial therapy Phase II Phase I P value* Hours after + meca gene test 7.7± ± Hours after + blood culture 39.3 ± ± Blood culture Positive meca gene Preliminary Final Drawn Blood culture test report susceptibility susceptibility I: 26.8 ± 14.4 II: 26.9 ± 10.4 (P=0.96) I: 28.1 ± 12.4 II: 28.5 ± 11.5 (P=0.90) I: 18.2 ± 1.4 II: 18.3 ± 1.3 (P=0.92) I: 49.7 ± 30.6 II: 53.8 ± 39.3 (P=0.72) I: 46.3 ± 12.9 II: 45.7 ± 12.6 (P=0.87) *Phase I vs Phase II

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated

More information

LINEE GUIDA: VALORI E LIMITI

LINEE GUIDA: VALORI E LIMITI Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions

More information

Annals of Clinical Microbiology and Antimicrobials. Open Access RESEARCH. Davie Wong 1*, Titus Wong 2,3, Marc Romney 2,4 and Victor Leung 2,4

Annals of Clinical Microbiology and Antimicrobials. Open Access RESEARCH. Davie Wong 1*, Titus Wong 2,3, Marc Romney 2,4 and Victor Leung 2,4 DOI 10.1186/s12941-016-0143-3 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Comparative effectiveness of β lactam versus vancomycin empiric therapy in patients with methicillin

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons

More information

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis

Barriers to Intravenous Penicillin Use for Treatment of Nonmeningitis JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights

More information

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov

More information

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University

More information

ANTIMICROBIAL SUSCEPTIBILITY CHARACTERIZING SUSCEPTIBILITY PATTERNS OF MSSA ASSOCIATED WITH SURGICAL WOUND INFECTIONS

ANTIMICROBIAL SUSCEPTIBILITY CHARACTERIZING SUSCEPTIBILITY PATTERNS OF MSSA ASSOCIATED WITH SURGICAL WOUND INFECTIONS ASSOCIATED WITH SURGICAL WOUND INFECTIONS Specimen ES-02 was designated as a "surgical wound culture" to be identified to the species level and tested for antimicrobial susceptibility. 1-4 The culture

More information

Objectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS

Objectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,

More information

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care

Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Jennifer McCann, PharmD, BCCCP State Director of Clinical Pharmacy Services St. Vincent Health Indiana Conflicts of Interest No

More information

Can we trust the Xpert?

Can we trust the Xpert? Can we trust the Xpert? An evaluation of the Xpert MRSA/SA BC System and an assessment of potential clinical impact Dr Kessendri Reddy Division of Medical Microbiology, NHLS Tygerberg Fakulteit Geneeskunde

More information

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)

IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,

More information

Jump Starting Antimicrobial Stewardship

Jump Starting Antimicrobial Stewardship Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing

More information

Is Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?

Is Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia? ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2011, p. 5122 5126 Vol. 55, No. 11 0066-4804/11/$12.00 doi:10.1128/aac.00485-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Is Cefazolin

More information

Impact of Antimicrobial Stewardship Program

Impact of Antimicrobial Stewardship Program Impact of Antimicrobial Stewardship Program Ripal Joshi, Pharm.D. AAHIVP Tampa General Hospital January 28, 2016 Objectives Provide an overview on antimicrobial stewardship programs (ASP) Describe the

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

FM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...

FM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment... Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo

More information

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health

More information

Burden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital

Burden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity

More information

Understand the application of Antibiotic Stewardship regulations in LTC. Understand past barriers to antibiotic management concepts

Understand the application of Antibiotic Stewardship regulations in LTC. Understand past barriers to antibiotic management concepts Objectives Understand the application of Antibiotic Stewardship regulations in LTC Understand past barriers to antibiotic management concepts Understand benefits of adoption of antibiotic stewardship regulations

More information

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Bradley M. Wright 1 and Edward H. Eiland III Introduction

Bradley M. Wright 1 and Edward H. Eiland III Introduction SAGE-Hindawi Access to Research Journal of Pathogens Volume 2011, Article ID 347969, 6 pages doi:10.4061/2011/347969 Clinical Study Retrospective Analysis of Clinical and Cost Outcomes Associated with

More information

Evaluating the Role of MRSA Nasal Swabs

Evaluating the Role of MRSA Nasal Swabs Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization

More information

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD

Antimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an

More information

Le infezioni di cute e tessuti molli

Le infezioni di cute e tessuti molli Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections

More information

Antimicrobial Stewardship

Antimicrobial Stewardship Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required

More information

Staph Cases. Case #1

Staph Cases. Case #1 Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Empiric therapy for severe suspected Staphylococcus aureus infection

Empiric therapy for severe suspected Staphylococcus aureus infection Empiric therapy for severe suspected Staphylococcus aureus infection Salman Qureshi, MD McGill University Faculty of Medicine Department of Critical Care Medicine McGill University Health Centre Relevant

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

Management of Native Valve

Management of Native Valve Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis

More information

Antimicrobial Stewardship 101

Antimicrobial Stewardship 101 Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Annual Surveillance Summary: Methicillin- Resistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2016

Annual Surveillance Summary: Methicillin- Resistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2016 Annual Surveillance Summary: Methicillin- Resistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2016 Jessica Spencer and Uzo Chukwuma Approved for public release. Distribution

More information

Int.J.Curr.Microbiol.App.Sci (2018) 7(8):

Int.J.Curr.Microbiol.App.Sci (2018) 7(8): International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

Collecting and Interpreting Stewardship Data: Breakout Session

Collecting and Interpreting Stewardship Data: Breakout Session Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline

More information

New Antibiotics for MRSA

New Antibiotics for MRSA New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

ANTIBIOTICS IN THE ER:

ANTIBIOTICS IN THE ER: ANTIBIOTICS IN THE ER: EXPLORING THE ROLE OF ANTIMICROBIAL STEWARDSHIP IN THE EMERGENCY DEPARTMENT ANGELINA DAVIS, PHARMD, MS, BCPS (AQ-ID) LIAISON CLINICAL PHARMACIST DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH

More information

Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship

Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases

More information

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply. Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted

More information

Rapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management. Martin McHugh Clinical Scientist

Rapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management. Martin McHugh Clinical Scientist Rapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management Martin McHugh Clinical Scientist 1 Staphylococcal Bacteraemia SAB is an important burden on

More information

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

More information

Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective

Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective James E. Kirby, MD D(ABMM) Medical Director, Clinical Microbiology Beth

More information

Bugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care

Bugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care Bugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care Molly Curran, PharmD, BCPS Clinical Assistant Professor The University of Texas College of Pharmacy Clinical

More information

Antimicrobial Stewardship:

Antimicrobial Stewardship: Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of

More information

Considerations for antibiotic therapy. Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen

Considerations for antibiotic therapy. Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen Considerations for antibiotic therapy Christoph K. Naber Interventional Cardiology Heartcenter - Elisabeth Hospital Essen Infective Endocarditis There will never be a cure for this malignant disease! Sir

More information

Appropriate Antimicrobial Therapy for Treatment of

Appropriate Antimicrobial Therapy for Treatment of Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul

More information

Annual Surveillance Summary: Methicillinresistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2017

Annual Surveillance Summary: Methicillinresistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2017 Annual Surveillance Summary: Methicillinresistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2017 Jessica R. Spencer and Uzo Chukwuma Approved for public release. Distribution

More information

NUOVE IPOTESI e MODELLI di STEWARDSHIP

NUOVE IPOTESI e MODELLI di STEWARDSHIP Esperienze di successo di antimicrobial stewardship Bologna, 18 novembre 2014 NUOVE IPOTESI e MODELLI di STEWARDSHIP Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Interventions

More information

Using Data to Track Antibiotic Use and Outcomes

Using Data to Track Antibiotic Use and Outcomes Using Data to Track Antibiotic Use and Outcomes Michelle Nemec, PharmD Thrifty White Drug Pharmacy Objectives Describe the Antibiotic Stewardship Core Element of tracking and the specific interventions

More information

TITLE: NICU Late-Onset Sepsis Antibiotic Practice Guideline

TITLE: NICU Late-Onset Sepsis Antibiotic Practice Guideline Site: Saint Joseph Hospital - NICU Original Effective Date: 6/1/2016 Next Review Date: 6/1/2019 TITLE: Practice Guideline Purpose: Timely and appropriate treatment of late-onset sepsis with antibiotic

More information

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance

More information

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain

More information

Antimicrobial Chemotherapy

Antimicrobial Chemotherapy 2016 edition by Claudine El-Beyrouty, PharmD, BCPS Department of Pharmacy Thomas Jefferson University Hospital Brian Roslund, PharmD, BCPS, AQ-ID Department of Pharmacy Thomas Jefferson University Hospital

More information

CME/SAM. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting

CME/SAM. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting Microbiology and Infectious Disease / Xpert MRSA/SA in Pediatric Blood Cultures Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting David H. Spencer, MD, PhD,

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Antibiotic Stewardship in the LTC Setting

Antibiotic Stewardship in the LTC Setting Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship

More information

Incidence of hospital-acquired Clostridium difficile infection in patients at risk

Incidence of hospital-acquired Clostridium difficile infection in patients at risk Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida All Publications 5-20-2016 Incidence of hospital-acquired Clostridium difficile infection in patients at risk Christine Ibarra

More information

Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia

Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia RESEARCH ARTICLE Open Access Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia Marin L Schweizer 1,2,3*, Jon P Furuno 1,

More information

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients

UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management

More information

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and

More information

Best Antimicrobials for Staphylococcus aureus Bacteremia

Best Antimicrobials for Staphylococcus aureus Bacteremia Best Antimicrobials for Staphylococcus aureus Bacteremia I. Methicillin Susceptible Staph aureus (MSSA) A. In vitro - Anti-Staphylococcal β-lactams (Oxacillin, Nafcillin, Cefazolin) are more active B.

More information

Antibacterials. Recent data on linezolid and daptomycin

Antibacterials. Recent data on linezolid and daptomycin Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons

More information

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

Antimicrobial Stewardship In Residential Aged Care Facilities

Antimicrobial Stewardship In Residential Aged Care Facilities Poster Session HRT11420 Innovation Awards November 2014 Melbourne Antimicrobial Stewardship In Residential Aged Care Facilities Elizabeth Orr: Monash Health: Elevator Pitch- A pilot project was conducted

More information

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE Crisis: Antibiotic Resistance Success Strategy WWW.optimistic-care.org

More information

Define evidence based practices for selection and duration of antibiotics to treat suspected or confirmed neonatal sepsis

Define evidence based practices for selection and duration of antibiotics to treat suspected or confirmed neonatal sepsis GLOBAL AIM: Antibiotic Stewardship Perinatal Quality Improvement Teams (PQITs) will share strategies and lessons learned to develop potentially better practices and employ QI methodologies to establish

More information

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23

More information

POTENTIAL STRUCTURE INDICATORS FOR EVALUATING ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN EUROPEAN HOSPITALS

POTENTIAL STRUCTURE INDICATORS FOR EVALUATING ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN EUROPEAN HOSPITALS POTENTIAL STRUCTURE INDICATORS FOR EVALUATING ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN EUROPEAN HOSPITALS Dirk VOGELAERS Department of General Internal Medicine, Infectious Diseases and Psychosomatic Medicine

More information

STAPHYLOCOCCI: KEY AST CHALLENGES

STAPHYLOCOCCI: KEY AST CHALLENGES Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection

More information

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus

Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings

More information

Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP

Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical

More information

Advancing Antimicrobial Stewardship in Community and Rural Hospitals

Advancing Antimicrobial Stewardship in Community and Rural Hospitals Advancing Antimicrobial Stewardship in Community and Rural Hospitals Whitney Buckel, PharmD, BCPS Infectious Diseases Clinical Pharmacist Intermountain Medical Center Disclosures The SCORE study was supported

More information

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection

More information

Telligen Outpatient Antibiotic Stewardship Initiative. The Renal Network March 1, 2017

Telligen Outpatient Antibiotic Stewardship Initiative. The Renal Network March 1, 2017 Telligen Outpatient Antibiotic Stewardship Initiative The Renal Network March 1, 2017 Who is Telligen? What is the QIN-QIO Program? Telligen: The Medicare Quality Innovation Network (QIN)-Quality Improvement

More information

Antibiotic Stewardship: The Facility Role and Implementation. Tim Cozad, LPN, Lead LTC Health Facilities Surveyor

Antibiotic Stewardship: The Facility Role and Implementation. Tim Cozad, LPN, Lead LTC Health Facilities Surveyor Antibiotic Stewardship: The Facility Role and Implementation Tim Cozad, LPN, Lead LTC Health Facilities Surveyor Phase II CMS Regulatory Changes Current information available includes: New Survey Process

More information

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT

More information

ANTIBIOTIC STEWARDSHIP

ANTIBIOTIC STEWARDSHIP ANTIBIOTIC STEWARDSHIP S.A. Dehghan Manshadi M.D. Assistant Professor of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences Issues associated with use of antibiotics were recognized

More information

Antimicrobial Resistance

Antimicrobial Resistance Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

Antimicrobial Resistance Acquisition of Foreign DNA

Antimicrobial Resistance Acquisition of Foreign DNA Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple

More information

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Antimicrobial stewardship

Antimicrobial stewardship Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the

More information

Jerome J Schentag, Pharm D

Jerome J Schentag, Pharm D Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday

More information

General Approach to Infectious Diseases

General Approach to Infectious Diseases General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor

More information

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and PCR-based rapid diagnosis of Staphylococcus aureus bacteraemia

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and PCR-based rapid diagnosis of Staphylococcus aureus bacteraemia ORIGINAL ARTICLE BACTERIOLOGY Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and PCR-based rapid diagnosis of Staphylococcus aureus bacteraemia O. Clerc 1, G. Prod hom 2,

More information

Unasyn alternative if penicillin allergic

Unasyn alternative if penicillin allergic Unasyn alternative if penicillin allergic The following guidelines have been developed to assist physicians with the appropriate selection of prophylactic and empiric antibiotic therapy for potential and.

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

Antimicrobial Stewardship in the Hospital Setting

Antimicrobial Stewardship in the Hospital Setting GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 12 Antimicrobial Stewardship in the Hospital Setting Authors Dan Markley, DO, MPH, Amy L. Pakyz, PharmD, PhD, Michael Stevens, MD, MPH Chapter Editor

More information

Sustaining an Antimicrobial Stewardship

Sustaining an Antimicrobial Stewardship Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial

More information

1 Beth Israel Deaconess Medical Center, Boston, MA, US. 2 J&P MEDICAL RESEARCH LTD., Vienna, Austria and

1 Beth Israel Deaconess Medical Center, Boston, MA, US. 2 J&P MEDICAL RESEARCH LTD., Vienna, Austria and AAC Accepts, published online ahead of print on 23 November 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00348-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.

More information

What is an Antibiotic Stewardship Program?

What is an Antibiotic Stewardship Program? What is an Antibiotic Stewardship Program? Jane Rogers, R.N. Anne Messer, MPH Learning Session #4 August 15, 2017 National Nursing Home Quality Care Collaborative Change Package Change Bundle: To prevent

More information

Suitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)

Suitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP) STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information